Fig. 1 · Structure

Documents & Downloads

GSK2636771

Cat. No. A11784 CAS 1372540-25-4

PI3K Inhibitor

GSK2636771 is a potent, orally bioavailable, PI3K beta-selective inhibitor.

In Stock

Publications for GSK2636771

2 publications citing this product

  1. Sarah E Conduit, .et al. , Nat Commun, 2024, Aug 21;15(1):7181 PMID: 39168978
  2. Pridham KJ, .et al. , Neuro Oncol, 2018, Mar 27;20(4):494-505 PMID: 29016844

Free Aliquoting for Your Order

Tell us your preferred amount per vial. We’ll confirm the options.

Biological Activity

Bioactivity / Mechanism

GSK2636771 is a PI3Kβ-selective inhibitor. In human enzyme assays, its PI3Kβ IC50 was 5.2 ± 2.9 nM (mean ± SD), compared with 58 ± 32 nM for PI3Kδ, >5,800 nM for PI3Kα and >12,600 nM for PI3Kγ. These biochemical potency values are assay endpoints, not cellular treatment concentrations. [1]

Literature-reported observations and conditions; not Adooq-tested protocols or general treatment recommendations.

Target & Activity

Target Activity Value
PI3Kβ

Cellular Effect

Cell Line Activity Value Description Reference
LNCaP EC50 178 nM Inhibition of PI3Kbeta in PTEN-deficient human LNCAP cells assessed as reduction in AKT phosphorylation at Ser473 residue after 2 hrs by mesoscale assay [PMID: 32551006]
LNCaP EC50 42 nM Inhibition of PI3Kbeta in PTEN-deficient human LNCaP C4-2 cells assessed as reduction in AKT phosphorylation at Ser473 residue after 2 hrs by mesoscale assay [PMID: 32551006]
MDA-MB-415 EC50 40 nM Inhibition of PI3Kbeta in PTEN-deficient human MDA-MB-415 cells assessed as reduction in AKT phosphorylation at Ser473 residue after 2 hrs by mesoscale assay [PMID: 32551006]
PC-3 EC50 23 nM Inhibition of PI3Kbeta in PTEN-deficient human PC3 cells assessed as reduction in AKT phosphorylation at Ser473 residue after 2 hrs by mesoscale assay [PMID: 32551006]
Sf21 IC50 25 nM Inhibition of recombinant human full-length N-terminal His6-tagged p110beta/human recombinant full-length untagged p85alpha expressed in baculovirus infected Sf21 insect cells using PIP2 as substrate after 30 mins in presence of ATP at 2xKm concentration [PMID: 32551006]
ZR-75-1 EC50 28 nM Inhibition of PI3Kbeta in PTEN-deficient human ZR-75-1 cells assessed as reduction in AKT phosphorylation at Ser473 residue after 2 hrs by mesoscale assay [PMID: 32551006]

In Vitro Studies

In hTERT-RPE1 cells, 1 μM GSK2636771 partially inhibited serum- and LPA-induced primary cilia disassembly after 1 h pretreatment and 24 h stimulation with inhibitor present. The study explicitly identifies Adooq A11784. The partial response supports a contribution of PI3Kβ within a broader cilia disassembly network. [2]

GBM cell responses varied with the model. After 4 days, GSK2636771 MTS viability IC50 values were 14.8 μM in U87MG and 15.7 μM in SF-295, versus reported fitted values of 140.6 μM in A172 and 62.7 μM in LN229. The latter estimates exceed the displayed dose range through 25 μM. [3]

PI3K isoform enzyme inhibition

Biochemical assay · Human PI3K isoform biochemical activity assays [1]

GSK2636771 inhibited PI3Kβ more potently than PI3Kα, PI3Kδ or PI3Kγ. Enzyme IC50 values and SD are distinct from the kinobead binding values in the adjacent column.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Human PI3Kβ enzyme inhibitionIC50 (mean ± SD where shown) 5.2 ± 2.9 nM[1]
Human PI3Kα enzyme inhibitionIC50 (mean ± SD where shown) >5,800 nM[1]
Human PI3Kδ enzyme inhibitionIC50 (mean ± SD where shown) 58 ± 32 nM[1]
Human PI3Kγ enzyme inhibitionIC50 (mean ± SD where shown) >12,600 nM[1]

Literature-Reported Treatment Conditions

Method
PI3-Kinase HTRF assay (EMD Millipore); comparison across human PI3K isoforms
Reported limits
Assay concentrations, ATP concentration, incubation duration and replicate n are not specified in the reviewed assay description. No treatment dose inferred from IC50.
Methods and source locations

Compound reported in the paper: GSK2636771

Evidence concerns the material tested in this paper; it does not validate a current catalog lot or an alternative salt/form.

Accepted manuscript pp. 7–8; Fig. 1A–B on p. 36 and caption p. 33

Human PI3Kβ enzyme inhibition: Biochemical activity assay; mean IC50 ± SD column; replicate n not stated. — Fig. 1B enzyme assay column, accepted manuscript p. 36; selectivity methods p. 8

Human PI3Kα enzyme inhibition: Biochemical activity assay; mean IC50 ± SD column; replicate n not stated. — Fig. 1B enzyme assay column, accepted manuscript p. 36; selectivity methods p. 8

Human PI3Kδ enzyme inhibition: Biochemical activity assay; mean IC50 ± SD column; replicate n not stated. — Fig. 1B enzyme assay column, accepted manuscript p. 36; selectivity methods p. 8

Human PI3Kγ enzyme inhibition: Biochemical activity assay; mean IC50 ± SD column; replicate n not stated. — Fig. 1B enzyme assay column, accepted manuscript p. 36; selectivity methods p. 8

Partial inhibition of induced cilia disassembly

Cell-based study · Parental human hTERT-RPE1 retinal pigment epithelial cells [2]

GSK2636771 partially impaired serum- and LPA-induced cilia disassembly compared with DMSO. This is a cellular phenotype supporting a contribution of PI3Kβ, rather than proof that PI3Kβ alone controls disassembly.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Percentage of ciliated cells after induced disassemblyQualitative direction; sampling and error semantics Partial inhibition under serum and LPA stimulation; 100 cells/condition; n = 6 (serum), n = 5 (LPA) independent experiments; mean ± SD[2]

Literature-Reported Treatment Conditions

Treatment concentration
1 μM
Exposure duration
1 h pretreatment followed by 24 h stimulation with inhibitor present; prior serum starvation 48 h
Method
Cilia scoring after serum or 2 μM LPA stimulation
Vehicle
DMSO
Co-treatment
Serum or LPA are disassembly stimuli, not a second inhibitor.
Reported limits
Final DMSO percentage not specified in the selected assay description. Exact ciliated-cell means are not extracted from bars.
Methods and source locations

Compound reported in the paper: GSK2636771

Evidence concerns the material tested in this paper; it does not validate a current catalog lot or an alternative salt/form.

Results Par21–Par22; Fig. 3f; Methods, Cell culture, cilia assembly/disassembly assay paragraph

Percentage of ciliated cells after induced disassembly: Fig. 3f; one-way ANOVA with Tukey post hoc per Statistics & reproducibility. Overall ANOVA p = 1.06 × 10−6 (serum), p = 0.0043 (LPA); these are not GSK-versus-DMSO pairwise p-values. — Fig. 3f image and caption; Results Par22; Methods, Statistics & reproducibility

Model-dependent GBM cell viability response

Cell-based study · U87MG, SF-295, A172 and LN229 human GBM cell lines [3]

GSK2636771 suppressed viability more strongly in p110β-high U87MG and SF-295 than in p110β-low A172 and LN229 cells. Reported fitted IC50 values for the low-response lines exceed the displayed concentration range.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
U87MG cell viabilityIC50 14.8 μM[3]
SF-295 cell viabilityIC50 15.7 μM[3]
A172 cell viabilityIC50 140.6 μM[3]
LN229 cell viabilityIC50 62.7 μM[3]

Literature-Reported Treatment Conditions

Treatment concentration
Displayed dose-response series through 25 μM; no IC50 value treated as an administered concentration
Exposure duration
4 days
Method
MTS viability assay; IC50 calculated using GraphPad Prism
Vehicle
DMSO; final percentage not specified
Reported limits
Independent replicate n and figure-specific MTS error-bar definition are not specified in the Fig. 5 caption. Values exceeding 25 μM are fitted estimates beyond the displayed range.
Methods and source locations

Compound reported in the paper: GSK2636771

Evidence concerns the material tested in this paper; it does not validate a current catalog lot or an alternative salt/form.

Fig. 5A and caption; Methods, Cell Viability and Growth; Results, PI3K Isoform-Selective Inhibitors as a New Treatment for GBM

U87MG cell viability: MTS assay after 4 days; figure-printed fitted IC50, not an enzyme potency. A172 and LN229 values exceed the displayed tested range. — Fig. 5A printed IC50 table; Methods, Cell Viability and Growth

SF-295 cell viability: MTS assay after 4 days; figure-printed fitted IC50, not an enzyme potency. A172 and LN229 values exceed the displayed tested range. — Fig. 5A printed IC50 table; Methods, Cell Viability and Growth

A172 cell viability: MTS assay after 4 days; figure-printed fitted IC50, not an enzyme potency. A172 and LN229 values exceed the displayed tested range. — Fig. 5A printed IC50 table; Methods, Cell Viability and Growth

LN229 cell viability: MTS assay after 4 days; figure-printed fitted IC50, not an enzyme potency. A172 and LN229 values exceed the displayed tested range. — Fig. 5A printed IC50 table; Methods, Cell Viability and Growth

In Vivo Studies

Oral GSK2636771 inhibited growth of subcutaneous PC3 xenografts in female nude mice during 21 days of daily treatment. The plotted 10 mg/kg group showed greater separation from vehicle than the 1 and 3 mg/kg groups. The experiment used eight mice per group and does not establish activity in intracranial tumors. [1]

In a separate U87MG subcutaneous xenograft experiment, GSK2636771 at 30 mg/kg intraperitoneally each day for 2 weeks produced only marginal growth inhibition versus DMSO control (P = 0.096). This result limits a general claim of glioblastoma efficacy; the significant TGX-221 comparator response belongs to a different compound. [3]

Marginal U87MG xenograft response

Animal study · Subcutaneous U87MG xenografts in severe combined immunodeficient/beige mice [3]

At 30 mg/kg daily intraperitoneally, GSK2636771 produced only marginal tumor-growth inhibition versus control (P = 0.096). The result does not establish statistically significant efficacy at a 0.05 threshold. The TGX-221 comparator was significant (P = 0.029), which cannot be assigned to GSK2636771.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
U87MG xenograft tumor-volume comparisonP-value P = 0.096 (GSK2636771 versus control)[3]

Conditions shared by the study groups

Route
Intraperitoneal
Frequency
Daily
Treatment course
2 weeks; results describe treatment from day 6 to day 20
Vehicle
DMSO control; exact administered formulation not specified
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
GSK2636771 monotherapy
30 mg/kg
DMSO vehicle groupMarginal growth inhibition; P = 0.096 versus control.[3]
GSK2636771 monotherapy
Model: U87MG subcutaneous xenografts; SCID/beige mice
Reported limits: 4 or 5 tumors contribute to standard errors; exact animals per arm and formulation concentrations not specified.
Methods and source locations

Compound reported in the paper: GSK2636771

Evidence concerns the material tested in this paper; it does not validate a current catalog lot or an alternative salt/form.

Fig. 5H and caption; Methods, Mouse Models; Results, PI3K Isoform-Selective Inhibitors as a New Treatment for GBM

U87MG xenograft tumor-volume comparison: t-test per Fig. 5H caption; error bars are standard errors from 4 or 5 tumors. — Fig. 5H image and caption; Results, paragraph beginning To determine the therapeutic potential

GSK2636771 monotherapy · Fig. 5H; Methods, Mouse Models; Results, in vivo paragraph

PC3 xenograft growth inhibition

Animal study · Subcutaneous PC3 prostate cancer xenografts in female nude mice [1]

GSK2636771 inhibited tumor growth in the PC3 model, with greater visual separation from vehicle at the higher plotted doses. These data are model-specific and do not establish glioblastoma efficacy or brain penetration.

Conditions shared by the study groups

Route
Oral gavage
Frequency
Once daily
Treatment course
21 days
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
GSK2636771 1 mg/kgVehicle-treated PC3 xenograftsTumor growth reduced relative to vehicle; 10 mg/kg shows greater separation than 1 or 3 mg/kg in the plotted curves.[1]
GSK2636771 3 mg/kgVehicle-treated PC3 xenograftsTumor growth reduced relative to vehicle; 10 mg/kg shows greater separation than 1 or 3 mg/kg in the plotted curves.[1]
GSK2636771 10 mg/kgVehicle-treated PC3 xenograftsTumor growth reduced relative to vehicle; 10 mg/kg shows greater separation than 1 or 3 mg/kg in the plotted curves.[1]
GSK2636771 1 mg/kg
Model: Female nude mice bearing PC3 xenografts; randomized n = 8/group
Reported limits: Vehicle composition and exact tumor-growth inhibition percentage not specified in reviewed main text/figure.
GSK2636771 3 mg/kg
Model: Female nude mice bearing PC3 xenografts; randomized n = 8/group
Reported limits: Vehicle composition and exact tumor-growth inhibition percentage not specified in reviewed main text/figure.
GSK2636771 10 mg/kg
Model: Female nude mice bearing PC3 xenografts; randomized n = 8/group
Reported limits: Vehicle composition and exact tumor-growth inhibition percentage not specified in reviewed main text/figure.
Methods and source locations

Compound reported in the paper: GSK2636771

Evidence concerns the material tested in this paper; it does not validate a current catalog lot or an alternative salt/form.

Accepted manuscript pp. 9,14; Fig. 1F on p. 36 and caption p. 33

GSK2636771 1 mg/kg · Fig. 1F and caption, accepted manuscript pp. 33,36; in vivo methods p. 9

GSK2636771 3 mg/kg · Fig. 1F and caption, accepted manuscript pp. 33,36; in vivo methods p. 9

GSK2636771 10 mg/kg · Fig. 1F and caption, accepted manuscript pp. 33,36; in vivo methods p. 9

Specifications

Manufacturer Adooq Bioscience
Actions Inhibitor
CAS Number 1372540-25-4
Applications PI3K Inhibitor
Formula C22H22F3N3O3
Molecular Weight 433.4
SMILES
CC1=C(C=CC=C1C(F)(F)F)CN2C(=NC3=C2C=C(C=C3C(=O)O)N4CCOCC4)C

Storage & Solubility

In Vitro Solubility

Reported Solubility

SolventReported Solubility
DMSO 28 mg/mL (64.6 mM)
Water Insoluble
Ethanol Insoluble

Preparing Stock Solutions

Stock preparation is unavailable for this product molecular weight.

Calculated stock concentrations do not establish solvent solubility. Refer to the reported solubility data for experimental guidance.

Storage

Store powder at -20°C, keep desiccated.
In powder form, the chemical is stable for 36 months.
In solution, store at -20°C and use within 1 month to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.

Research References

  1. [1] Mateo J, Ganji G, Lemech C, et al. A First-Time-in-Human Study of GSK2636771, a Phosphoinositide 3 Kinase Beta-Selective Inhibitor, in Patients with Advanced Solid Tumors. Clinical cancer research : an official journal of the American Association for Cancer Research (2017). PMID: 28645941 DOI: 10.1158/1078-0432.ccr-17-0725 Source material
  2. [2] Conduit SE, Pearce W, Bhamra A, et al. A class I PI3K signalling network regulates primary cilia disassembly in normal physiology and disease. Nature communications (2024). PMID: 39168978 DOI: 10.1038/s41467-024-51354-1 Source material
  3. [3] Pridham KJ, Le L, Guo S, et al. PIK3CB/p110β is a selective survival factor for glioblastoma. Neuro-oncology (2018). PMID: 29016844 DOI: 10.1093/neuonc/nox181 Source material

Publications

2 publications citing this product

  1. Sarah E Conduit, .et al. , Nat Commun, 2024, Aug 21;15(1):7181 PMID: 39168978
  2. Pridham KJ, .et al. , Neuro Oncol, 2018, Mar 27;20(4):494-505 PMID: 29016844

Added to your cart

View Cart Checkout
Loading...